Data Characteristics
Bioequivalence (BE) clinical trial prescreening relies on data from drug clinical trial databases, pharmacokinetic (PK) literature reports, in vitro dissolution data, and drug physicochemical property databases. This data typically exists as structured tables, PDF reports (including charts and text descriptions), XML files, or output files from specialized PK analysis software.
Public databases like ClinicalTrials.gov and the FDA Orange Book update regularly. Specific drug PK/BE study reports update less frequently, often released when a new drug launches or a generic drug is submitted for approval.
PK/BE reports usually include study protocols, subject information, dosing regimens, plasma concentration-time curves, PK parameters (e.g., AUC, Cmax, Tmax), and statistical analysis results. Common fields include subject ID, dosage, blood sampling time points, plasma concentration (typically in ng/mL or µg/mL), batch number, and formulation type (reference/test formulation).
Constraints on Reference and Traceability
The diversity and specialized nature of bioequivalence data impose specific requirements on reference and traceability.
First, identifying unstructured tables and charts in PDF reports is critical. The system must accurately extract core data, such as plasma concentrations, and link it to the original chart or table region.
Second, PK parameter calculation and referencing require a strict statistical background. The model must differentiate between raw data and derived parameters when citing, and trace back to specific calculation methods or statistical software versions.
Inconsistent data update frequencies necessitate clear publication dates for data sources in the knowledge base to avoid citing outdated information.
Consistency checks for specialized terminology and units are essential. For example, plasma concentration unit conversion (ng/mL to µg/mL) ensures numerical accuracy during citation.
Integrating information for the same drug from different heterogeneous sources and providing a unified citation path presents a challenge in this area.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
Chunk size (Segment Length) | 800–1200 characters | Balances the completeness of paragraphs in PK/BE reports with model context window limits, preventing critical information truncation. |
Recall count (Recall Count) | Top 8 | Ensures coverage of key PK parameter tables, plasma concentration curve descriptions, and statistical conclusions in reports, improving recall rate. |
Similarity threshold (Similarity Threshold) | 0.78 | This threshold effectively filters highly relevant segments and reduces noise in text dense with specialized terms and numerical values. |
Rerank result count (Rerank Return Count) | 5 | Further optimizes relevance through a reranking model based on recall, improving the accuracy of final citations. |
PARSE_FILE_TIMEOUT_SECONDS | 600 seconds | Accommodates parsing time for large PDF reports (e.g., hundreds of pages of plasma concentration data), preventing parsing failures due to timeouts. |
MAX_KNOWLEDGE_BASE_SIZE_MB | 1024 MB | Accounts for multiple PK/BE reports and related literature for a single drug, reserving sufficient knowledge base storage space. |
Common Pitfalls
- The model does not cite knowledge base content, or the cited content does not match the actual query. This may occur if the segment length is too long or the similarity threshold is set too high, preventing relevant segments from being effectively recalled.
- Cited PK parameter values in the output results are inconsistent with the original report. This manifests as incorrect plasma concentration units or statistical result discrepancies. The cause lies in the data preprocessing failing to correctly identify and standardize specialized units or distinguish between raw and derived data.
- When integrating multiple reports, the model cites an older version or a non-primary source of data. This manifests as outdated information in the results. The cause lies in the knowledge base failing to effectively manage the priority or publication date of different versions or data sources.
Validation Steps
- Select BE reports for several typical drugs. Query key PK parameters (e.g., AUC, Cmax) from these reports. Verify that the numerical values, units, and citations in the model's output are identical to the original reports.
- Query paragraphs containing charts in reports. Check if the model accurately identifies and cites chart titles or descriptions, validating its ability to parse unstructured data.
- Upload different versions of BE reports for the same drug. Ask about the latest PK data for that drug. Confirm the model prioritizes citing the newest version of the data, validating version management and source traceability.
- Simulate user queries containing specialized terminology or complex logic. Check if the model can recall and integrate information from multiple sources in the knowledge base and provide clear citation paths.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.